Regeneron’s Eylea: Pulling Open the Curtain on Drug Costs

Doris is 85 and suffers from moisture build up in her eye, what some call wet eye.   She is on Medicare and gets treated with Eylea, a Regeneron product, every 4-5 weeks.  Each treatment costing $6,200.   That is more than $70,000 per year even though Doris never made more than $40,000 while working. … Continue reading Regeneron’s Eylea: Pulling Open the Curtain on Drug Costs

Is Patient Health Being Mortgaged via Derivatives as Homes Were During the Financial Crisis?

    Senator McConnell's Dilemma:   To Serve Patients or Investors? When evaluating health care investments it is important to analyze the structure of leading drug and medical equipment companies.  A close look indeed reveals a derivative driven system in which private equity and hedge funds increase demand for drug payments by purchasing the rights … Continue reading Is Patient Health Being Mortgaged via Derivatives as Homes Were During the Financial Crisis?

Private Equity and Hedge Funds Employ Enron’s Tricks to Manipulate Health Care Grid

Disclosure and Media Development Background: ¬†Parish & Company maintains no speculative investments in the health care companies discussed and does not collaborate with any private equity or hedge funds. ¬†It's goal is to identify high quality health care opportunities suitable for long term oriented investment. This effort includes providing high quality news material to leading … Continue reading Private Equity and Hedge Funds Employ Enron’s Tricks to Manipulate Health Care Grid

The Oregonian Reports on Valuation Concerns Regarding PERS Private Equity Investments

In a front page story Sunday May 20, 2012, Ted Sickinger of the Oregonian provided a detailed review of private equity valuation concerns.  This portfolio of opaque investments has grown substantially and poses unique risks to Oregonian PERS participants.  In his article, Sickinger notes this analysis is based upon original Parish & Company research. Although … Continue reading The Oregonian Reports on Valuation Concerns Regarding PERS Private Equity Investments

Letter to SEC Chair and IRS Commissioner – Tax Deduction Pyramid Scheme

The following letter was sent to SEC Chair Mary Schapiro and IRS Commissioner Doug Shulman on "tax day" with the hope they will jointly work at restoring the integrity of cash flow statements, without question the most important analytical tool for investment advisors like myself.  It is simply astonishing, given their material nature, that listed … Continue reading Letter to SEC Chair and IRS Commissioner – Tax Deduction Pyramid Scheme

Blackstone Group LP – Private Equity or Public Theft? Undermining the Volcker Rule’s Intent. SEC 10K Fails to Disclose All Important “Fractions Rule” Involving Tax Exempt Public Pension Investors

Note (Not Copyrighted) : This basic post was updated December 10, 2010 given the current debate in Congress over extending the Bush tax cuts and numerous inquires regarding my position in this debate.  The purpose of this post is to highlight that although rates are important, perhaps more important are overall fairness issues associated with … Continue reading Blackstone Group LP – Private Equity or Public Theft? Undermining the Volcker Rule’s Intent. SEC 10K Fails to Disclose All Important “Fractions Rule” Involving Tax Exempt Public Pension Investors